Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma

IF 1.4 4区医学 Q4 HEMATOLOGY

Transfusion and Apheresis Science Pub Date : 2025-02-17 DOI:10.1016/j.transci.2025.104096

Yixuan Cheng , Sishi Xu , Renzhi Pei , Dong Chen , Xiaohong Du , Shuangyue Li , Xianxu Zhuang , Haihui Zhuang , Ying Fang , Mengjie Wu , Peipei Ye , Ying Lu

{"title":"Etoposide + cytarabine + pegfilgrastim versus cyclophosphamide + G-CSF for stem cell mobilization in patients with poorly mobilized multiple myeloma and lymphoma","authors":"Yixuan Cheng , Sishi Xu , Renzhi Pei , Dong Chen , Xiaohong Du , Shuangyue Li , Xianxu Zhuang , Haihui Zhuang , Ying Fang , Mengjie Wu , Peipei Ye , Ying Lu","doi":"10.1016/j.transci.2025.104096","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>In multiple myeloma (MM) or lymphoma with poor mobilization, the combination of etoposide, cytarabine (Ara-C), and pegfilgrastim (EAP) appears to have higher mobilization efficacy than cyclophosphamide (Cy) plus granulocyte colony-stimulating factor (G-CSF) (CG) regimens. The purpose of this study was to examine whether there were differences in efficacy and toxicity between the two mobilization regimens.</div></div><div><h3>Methods</h3><div>All data were collected from Department of Hematology at the Affiliated People's Hospital of Ningbo University from May 2016 to March 2023. And data from EAP regimen were compared with data from the CG regimen.</div></div><div><h3>Results</h3><div>A total of 43 patients were mobilized by the EAP regimen and 44 patients by the CG regimen. The target yield of 2 × 10<sup>6</sup> CD34<sup>+</sup> cells/kg was achieved in 95.3 % (EAP) and 63.6 % (CG) of patients by 1.3 and 1.6 apheresis (means), respectively. In addition, 76.7 % of patients with EAP regimen and 29.5 % of patients with CG regimen achieved optimal mobilization (≥5 ×10<sup>6</sup> CD34<sup>+</sup> cells/kg) during the first apheresis session. The median number of cumulative collected CD34<sup>+</sup> cells was 8.9 (range 2.6–41.3) × 10<sup>6</sup> CD34<sup>+</sup> cells/kg and 4.2 (range 0.1–18.8) × 10<sup>6</sup> CD34<sup>+</sup> cells/kg in the two groups, respectively. Thrombocytopenia gr. 4 was observed in 34.9 % of patients after EAP (CG, 2.3 %) and neutropenia gr. 4 was observed in 58.1 % of patients after EAP (CG, 63.6 %).</div></div><div><h3>Discussion</h3><div>EAP is an excellent mobilization regimen with acceptable toxicity and could be considered in patients with MM and lymphoma with poor mobilization.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 3","pages":"Article 104096"},"PeriodicalIF":1.4000,"publicationDate":"2025-02-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Transfusion and Apheresis Science","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1473050225000308","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

In multiple myeloma (MM) or lymphoma with poor mobilization, the combination of etoposide, cytarabine (Ara-C), and pegfilgrastim (EAP) appears to have higher mobilization efficacy than cyclophosphamide (Cy) plus granulocyte colony-stimulating factor (G-CSF) (CG) regimens. The purpose of this study was to examine whether there were differences in efficacy and toxicity between the two mobilization regimens.

Methods

All data were collected from Department of Hematology at the Affiliated People's Hospital of Ningbo University from May 2016 to March 2023. And data from EAP regimen were compared with data from the CG regimen.

Results

A total of 43 patients were mobilized by the EAP regimen and 44 patients by the CG regimen. The target yield of 2 × 10⁶ CD34⁺ cells/kg was achieved in 95.3 % (EAP) and 63.6 % (CG) of patients by 1.3 and 1.6 apheresis (means), respectively. In addition, 76.7 % of patients with EAP regimen and 29.5 % of patients with CG regimen achieved optimal mobilization (≥5 ×10⁶ CD34⁺ cells/kg) during the first apheresis session. The median number of cumulative collected CD34⁺ cells was 8.9 (range 2.6–41.3) × 10⁶ CD34⁺ cells/kg and 4.2 (range 0.1–18.8) × 10⁶ CD34⁺ cells/kg in the two groups, respectively. Thrombocytopenia gr. 4 was observed in 34.9 % of patients after EAP (CG, 2.3 %) and neutropenia gr. 4 was observed in 58.1 % of patients after EAP (CG, 63.6 %).

Discussion

EAP is an excellent mobilization regimen with acceptable toxicity and could be considered in patients with MM and lymphoma with poor mobilization.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Transfusion and Apheresis Science 医学-血液学

CiteScore

3.60

自引率

5.30%

发文量

181

审稿时长

42 days

期刊介绍： Transfusion and Apheresis Science brings comprehensive and up-to-date information to physicians and health care professionals involved in the rapidly changing fields of transfusion medicine, hemostasis and apheresis. The journal presents original articles relating to scientific and clinical studies in the areas of immunohematology, transfusion practice, bleeding and thrombotic disorders and both therapeutic and donor apheresis including hematopoietic stem cells. Topics covered include the collection and processing of blood, compatibility testing and guidelines for the use of blood products, as well as screening for and transmission of blood-borne diseases. All areas of apheresis - therapeutic and collection - are also addressed. We would like to specifically encourage allied health professionals in this area to submit manuscripts that relate to improved patient and donor care, technical aspects and educational issues. Transfusion and Apheresis Science features a "Theme" section which includes, in each issue, a group of papers designed to review a specific topic of current importance in transfusion and hemostasis for the discussion of topical issues specific to apheresis and focuses on the operators'' viewpoint. Another section is "What''s Happening" which provides informal reporting of activities in the field. In addition, brief case reports and Letters to the Editor, as well as reviews of meetings and events of general interest, and a listing of recent patents make the journal a complete source of information for practitioners of transfusion, hemostasis and apheresis science. Immediate dissemination of important information is ensured by the commitment of Transfusion and Apheresis Science to rapid publication of both symposia and submitted papers.